| Objective:To observe the clinical efficacy and safety of Yisui Shengbai Capsule in preventing and treating bone marrow suppression in patients with lung adenocarcinoma of spleen and kidney yang deficiency,so as to provide a more scientific and sufficient clinical basis for the wide application of this prescription.Methods:Patients with lung adenocarcinoma of spleen kidney yang deficiency type were randomly divided into control group(30 cases)and control group(30cases)by conventional chemotherapy with western medicine TP scheme(docetaxel+nedaplatin).The treatment group(30 cases)was treated with Yisui Shengbai Capsule on the basis of the control group.After 7,14 and 21 days of treatment,the peripheral blood picture(WBC,NEUT,PLT,HGB)and immune condition of the two groups were observed In order to evaluate the safety of Yisui Shengbai capsule,the clinical symptoms of traditional Chinese medicine and the changes of life quality before and after treatment were used to evaluate the clinical effect of Yisui Shengbai Capsule on the prevention and treatment of myelosuppression in patients with lung adenocarcinoma of spleen kidney yang deficiency type after chemotherapy.Spss22.0software was used for the analysis of all data in this experiment,with a statistical significance of P<0.05.Results:Among the 60 patients with lung adenocarcinoma of spleen and kidney yang deficiency type,3 patients withdrew and treated as shedding cases,so a total of57 cases were included in the statistical treatment(28 in the control group and 29 in the treatment group)),The specific results are as follows:(1)Changes of peripheral blood picture(WBC,NEUT,PLT,HGB):(1)There was no significant difference in WBC,NEUT,HGB and PLT between the two groups;(2)On the 7th day after chemotherapy,WBC and NEUT in the control group and the treatment group decreased significantly(P<0.05)compared with that before treatment,while the decrease of HGB and PLT in the treatment group was significantly lower than that in the control group(P<0.05).(3)On the 14th day after chemotherapy,WBC and NEUT of the two groups increased compared with the 7th day,and the treatment group was superior to the control group(P<0.05);PLT count level of the two groups decreased to the lowest level,which was statistically significant compared with that before treatment,and the decrease range of the treatment group was lower than that of the control group(P<0.05);HGB of the two groups increased compared with the 7th day,but there was no statistical significance.(4)On the 21st day after chemotherapy,WBC,NEUT,PLT in the treatment group were higher than those in the control group(P<0.05);WBC,NEUT,PLT in the control group were lower than those before treatment(P<0.05);WBC,NEUT,PLT in the treatment group were not significantly different from those before treatment(P>0.05)HGB in the two groups showed an upward trend compared with the 14th day,but there was no statistical significance(P>0.05).HGB in the two groups had no statistical significance compared with that before treatment(P>0.05).(2)Comparison of immune function between the two groups before and after treatment:After treatment,the levels of CD3~+,CD4~+and CD4~+/CD8~+in the control group decreased(P<0.05)and the level of CD8~+increased(P<0.05);in the treatment group CD3~+,CD4~+,CD8~+After treatment with CD4~+/CD8~+,there was no significant change compared with before treatment(P>0.05).Comparison between the groups found that the CD3~+,CD4~+and CD4~+/CD8~+of the control group after treatment were lower than that of the treatment group,which was statistically significant,and the CD8~+of the control group after treatment was higher than that of the treatment group,which had statistical significance.(3)Comparison of TCM clinical symptom scores:(1)There was no statistical difference between the two groups before and after treatment,and the difference was statistically significant;(2)The total score of clinical symptoms in the control group was higher than that before treatment(P<0.05);fatigue,sweating,night sweating and poor food intake were significantly worse than before treatment(P<0.05)and the other symptoms were no significant difference(P>0.05).(3)After treatment,the total score of clinical symptoms in the treatment group was lower than that before treatment(P<0.05);the fatigue of spirit,sweating and night sweating,and the difference of food intake were more serious than that before treatment(P>0.05),but there was no statistical significance;the symptoms in the treatment group were less than that before treatment(P<0.05).(4)Comparison of KPS scores between two groups:There was no significant difference in KPS score between the two groups before treatment.The KPS score of the treatment group was lower than that of the control group on the 21st day after chemotherapy.There was no significant difference in KPS score before and after chemotherapy in the treatment group;KPS score decreased in the control group after chemotherapy,which was statistically significant compared with that before chemotherapy.Conclusion:1.Yisui Shengbai capsule can improve the clinical symptoms of myelosuppression and improve the quality of life of patients with lung adenocarcinoma of spleen kidney yang deficiency type after chemotherapy.Its curative effect is definite,and there is no obvious adverse reaction.2.Yisui Shengbai capsule can improve the bone marrow suppression and immune ability of patients with lung adenocarcinoma of spleen kidney yang deficiency type after chemotherapy. |
PDF Full Text Request